12 Sep 2018 --- Life sciences company OptiBiotix Health has secured a deal with an unnamed US-based pharmaceutical company, enabling its Lactobacillus plantarum LPLDL probiotic to be developed as a biotherapeutic pharmaceutical product for the first time. The agreement grants the US partner exclusivity to the pharmaceutical market in the US with the option of expanding this worldwide in the future, totaling the milestone payments to seven-figures, as well as royalties on commercial sales, the company reports.
